ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 121,98
-0,90%
Dow Jones
39 806,77
-0,49%
DAX
18 673,23
-0,50%
Brent Oil
82,955
-0,69%
Bitcoin
71 048,80
-0,56%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Apellis Pharmaceuticals Inc (APLS)

  7. Apellis Pharmaceuticals Inc (APLS) Actualités

APLS

Apellis Pharmaceuticals (APLS)

Apellis Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:APLS
DateHeureSourceTitreSymboleSociété
14/05/202414h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APLSApellis Pharmaceuticals Inc
14/05/202414h00GlobeNewswire Inc.Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth StreetNASDAQ:APLSApellis Pharmaceuticals Inc
09/05/202423h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
08/05/202423h13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
07/05/202413h05GlobeNewswire Inc.Apellis Pharmaceuticals Reports First Quarter 2024 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
07/05/202413h02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:APLSApellis Pharmaceuticals Inc
06/05/202413h00GlobeNewswire Inc.Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
01/05/202413h00GlobeNewswire Inc.Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingNASDAQ:APLSApellis Pharmaceuticals Inc
26/04/202413h15GlobeNewswire Inc.Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)NASDAQ:APLSApellis Pharmaceuticals Inc
23/04/202413h00GlobeNewswire Inc.Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
04/04/202422h05GlobeNewswire Inc.Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:APLSApellis Pharmaceuticals Inc
01/04/202413h00GlobeNewswire Inc.Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
11/03/202412h00GlobeNewswire Inc.Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina AdvisorNASDAQ:APLSApellis Pharmaceuticals Inc
29/02/202423h10Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:APLSApellis Pharmaceuticals Inc
27/02/202413h35Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:APLSApellis Pharmaceuticals Inc
27/02/202413h05GlobeNewswire Inc.Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
27/02/202413h01Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:APLSApellis Pharmaceuticals Inc
26/02/202413h00GlobeNewswire Inc.Apellis Pharmaceuticals to Present at Upcoming Investor ConferencesNASDAQ:APLSApellis Pharmaceuticals Inc
20/02/202413h00GlobeNewswire Inc.Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
14/02/202423h18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:APLSApellis Pharmaceuticals Inc
14/02/202416h04Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:APLSApellis Pharmaceuticals Inc
26/01/202413h06GlobeNewswire Inc.Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of ApplicationNASDAQ:APLSApellis Pharmaceuticals Inc
08/01/202415h00GlobeNewswire Inc.Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product RevenuesNASDAQ:APLSApellis Pharmaceuticals Inc
02/01/202413h00GlobeNewswire Inc.Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
28/12/202313h00GlobeNewswire Inc.Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
14/12/202313h00GlobeNewswire Inc.Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European UnionNASDAQ:APLSApellis Pharmaceuticals Inc
11/12/202313h00GlobeNewswire Inc.EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual MeetingNASDAQ:APLSApellis Pharmaceuticals Inc
21/11/202313h00GlobeNewswire Inc.Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
04/11/202318h37GlobeNewswire Inc.SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)NASDAQ:APLSApellis Pharmaceuticals Inc
01/11/202312h51Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:APLSApellis Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:APLS

Dernières Valeurs Consultées

SPI
SP500
S&P 500
NYSE
NKE
Nike
COIN
BTCUSD
Bitcoin
EU
HO
Thales
NYSE
JPM
JP Morgan Chase
EU
CS
Axa
EU
RNO
Renault
NYSE
MCD
McDonalds
EU
CAP
Capgemini
NASDAQ
NVDA
NVIDIA
NASDAQ
AAPL
Apple
FTSE
UKX
FTSE 100
USI
USTECH100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés